Higher than the industry standard for maximum results
Individuals should consult a qualified healthcare professional before beginning any peptide protocol
Long-Term Weight Loss & Maintenance with Semaglutide in Obesity (2022 Review of STEP Trials) consolidates findings across multiple STEP trials (1, 3, 4, 8), showing 14.917.4% mean weight loss over 68 weeks, improved cardiometabolic markers, and better quality-of-life outcomes
Net loss was $5.0 million, or $0.21 per share, compared to net loss of $9.3 million, or $0.53 per share.
Click here for full Indications and Usage
Bear in mind that your tiredness on semaglutide is likely due to the reduced blood sugar and lower intake of calories that result from taking the drug